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Abstract: 
 
The hollow fiber assay (HFA) is a drug discovery tool to aid investigators in the prioritization of 
lead compounds identified by in vitro testing for further development in animal models of 
disease. In the HFA, cells are cultured in hollow fibers containing pores of a diameter (500 kDa) 
large enough for proteins and other macromolecules to enter, but too small for the cells to 
escape. The fibers are filled with cells, sealed and placed in the peritoneal cavity of 
immunodeficient mice. The mice undergo a predetermined treatment regimen after which the 
fibers are retrieved and the cells evaluated for activity of a target relevant to the disease modeled. 
The HFA combines advantages of both in vitro and in vivo assay systems. It uses the same cell 
lines used in culture systems, is a rapid assay, and requires fewer animals and less test substance 
than conventional xenograft systems. Like traditional in vivo assays, the test substance is 
evaluated in a live animal, which affords an initial assessment of associated toxicity and 
pharmacokinetic properties of the test substance. 
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Article: 
 
1. Introduction 
 
While the hollow fiber assay (HFA) can be adapted for a variety of uses (1, 2, 3, 4), our focus 
has been on the discovery of novel anticancer agents derived from natural sources such as fungi 
(5). Hollingshead and colleagues originally developed the assay as a means of prioritizing the 
many lead compounds that had been identified in the 60-cell line panel at the National Cancer 
Institute (NCI) (6). When the Cancer Chemotherapy National Service Center was established at 
the NCI in 1955, the primary screening tool was transplantable murine cancer models, which 
involved a vast number of mice. While these models were critical for the discovery of many 
effective anticancer agents used clinically, the leadership at the NCI decided that using human 
cancer cell lines would provide a greater diversity of targets relevant to human cancers and 
thereby increase the chance of success in their drug discovery program. Researchers at the NCI 
collected and characterized a panel of 60 cell lines representing cancers of the lung, colon, brain, 
ovary, breast, prostate, and kidney, together with leukemia and melanoma. These cells are also 
capable of propagating in immunodeficient mice as xerographs allowing for leads identified in 
the cell line panel to be followed up in vivo. As high-throughput and automated procedures were 
optimized using in vitro assays, in vivo models became the bottleneck for moving compounds 
forward in the drug discovery process. Since the HFA can be completed in about 1 week and 
requires only three mice per dose for each test substance, it allows investigators to prioritize lead 
compounds efficiently by saving time and using fewer animals (4). 
 
Fungi are recognized as one of the more significant sources of medicines and have provided a 
number of spectacular advances in the treatment of human diseases as is illustrated by the 
discovery of penicillin G, and the introduction of the first statins, for example. Even after 
decades of using fungal metabolites as leads for new drugs they remain a viable alternative to 
purely synthetic routes. For example, Gilenya™ (fingolimod, Novartis) is a compound based on 
myriocin, which is a metabolite first found in an insect-colonizing fungus, Isaria sinclairii. 
Gilenya™ was approved by the US Food and Drug Administration as the first orally active 
medicine for multiple sclerosis. These medicines represent the best of a very large catalogue of 
bioactive compounds produced by fungi. The chemical diversity of fungal metabolites is 
extraordinarily broad and this is reflected in their biological activity. 
 
A number of fungal metabolites and their derivatives have been evaluated clinically as potential 
cancer medicines; examples include brefeldin A, wortmannin, cytochalasin E, and related 
derivatives such as fumagillin, gliotoxin, terrecyclic acid A, the illudin derivative irofulvin, and 
lentinan and related polysaccharides which are approved for use in Japan. In our own program to 
find new cancer lead compounds funded by the NIH (Discovery of Anticancer Agents of Diverse 
Natural Origin. 5P01 CA125066; Principal Investigator, A.D. Kinghorn supported by the NCI, 
National Institutes of Health), over the course of the past 4 years we have discovered 102 
compounds, 31 of which are novel, that are active in our cultured cancer cell lines. Our other 
programs using vascular plants and cyanobacteria have also been successful in finding new 
compounds. This success means that we are in urgent need of secondary bioassays to help us 
focus on those leads with the highest probability of generating clinical lead-quality compounds, 
and the need for methods to evaluate compounds in vivo is especially useful. To this end we 
have been developing methods to provide such prioritization, and the HFA has been one 
approach we have taken. 
 
2. Materials 
 
2.1 Cell Culture Supplies 
 
1. Human cancer cell lines (American Type Culture Collection; see Note 1). 
 
2. RPMI 1640 medium with glutamine. 
 
3. Fetal bovine serum. 
 
4. Trypsin (0.05%)/EDTA. 
 
5. Antibiotic/antimitotic, 100× [contains penicillin (104 units/ml), streptomycin 
(104μg/ml), and the antifungal agent amphotericin B (25 μg/ml)]. 
 
6. Trypan blue solution (0.4%, Sigma Chemical Co.). 
 
7. MTT [3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide]. 
 
8. Tissue culture flasks (T75 and T150, BD Falcon). 
 
9. Sterile centrifuge tubes (15 and 50 ml, BD Falcon). 
 
10. Hemocytometer (Reichert Bright-Line, Hausser Scientific, Horsham, PA). 
  
2.2 Hollow Fiber Preparation 
 
1. Modified polyvinylidene difluoride hollow fibers (Spectrum Labs, CellMax®, 
molecular weight cutoff of 500 kDa). 
 
2. Dry glass bead sterilizer (see Note 2). 
 
3. Needle holders, forceps, and scissors. 
 
4. 1 and 5 ml syringes; needles. 
 
5. Stainless steel pan (approximately 10  ×  6.5 in.). 
 
6. Six-well culture plates. 
 
7. Medical gloves (latex or nitrile). 
 
2.3 Surgical Supplies 
 
1. Trocar (11 gauge; Popper and Sons, New Hyde Park, NY). 
 
2. Wound clip system (Autoclip®, Harvard Apparatus). 
 
3. General operating scissors. 
 
4. Dressing and tissue forceps. 
  
3. Methods 
 
3.1 Conditioning Fibers 
 
Wear gloves when handling fibers. 
 
1. Using a syringe fitted with either an 18 or 20 gauge needle, flush each fiber 
individually with 70% EtOH (Fig. 1). 
 
Figure 1. Sterilize the fibers. Flush the fibers with 70% ethanol using a syringe fitted with an 18 
or 20 gauge needle. 
 
2. Place fibers in an autoclavable covered pipette tray filled with 70% EtOH for at least 
72 h. Do not allow fibers to dry out from this point on. 
 
3. After 72 h, use a needle and syringe as above and flush fibers twice individually with 
deionized water. 
 
4. Place fibers in another pipette tray filled with deionized water and autoclave for 30 
min. Let cool and store at 4°C until fibers are needed. 
 
3.2 Cell Culture 
 
The reader is referred to books on cell culture for general procedures (7, 8). The cells are grown 
in RPMI 1640 medium supplemented with glutamine and 10% fetal bovine serum in T75 flasks 
(8). The split ratio is dependent on the rate of proliferation, which varies from line to line, but 
generally is between 1:3 and 1:10. Cells are split at a ratio that will result in 70–80% confluence 
on the experiment day. On the day before the experiment, cells are fed by removing half of the 
medium and adding an equal volume of fresh medium. On the day that the fibers are to be filled, 
the cells are washed with PBS, incubated with 1–3 ml of trypsin, and incubated for 5–10 min at 
37°C to detach them from the flask surface. The cells are resuspended in medium, counted using 
a hemocytometer, and plated in new flasks or injected into preconditioned hollow fibers. 
 
1. Pour off medium from cells into a sterile tube and place on ice (this conditioned 
medium will be used to resuspend the cells later); wash cells twice with PBS. 
 
2. Aspirate PBS and add 2 ml trypsin per flask. Incubate at 37°C for 5 min to detach the 
cells from the flasks. 
 
3. Add 10 ml fresh medium to flask; transfer medium and cells to a sterile centrifuge tube 
and centrifuge (5 min, 800  ×  g, 4°C); aspirate medium, resuspend cells in 5 ml 
conditioned medium, and place on ice. 
 
4. Determine viable cell number using the trypan blue dye exclusion test (9). 
 
5. Add the appropriate volume RPMI 1640 with FBS medium (20% vol/vol) to achieve 
the desired cell concentration and place on ice. 
 
3.3 Fiber Preparation 
 
Conditioning, filling, and sealing the hollow fibers must be conducted in a sterile environment. 
 
1. Mark the bottom of a stainless steel pan every 2 cm for work surface. Wrap the 
stainless steel pan in aluminum foil. Autoclave needle holder with scissors, smooth 
forceps, and stainless steel work surface (see Note 3). 
 
2. Empty a biosafety cabinet and wipe down with 70% EtOH. Place pipette tray 
containing fibers and bead sterilizer in the biosafety cabinet. Spray down the outside of 
the tray with EtOH. Allow bead sterilizer to heat to maximum temperature. 
 
3. Place centrifuge tubes of cells and media on ice. Set up a sterile field in the cabinet by 
placing sterile drapes on the work surface. Carefully unwrap the stainless steel work 
surface under the hood and place in the sterile field. Place all autoclaved instruments in 
the sterile field. Remove 10 and 1 ml syringes and 18 or 20 gauge needles from freezer 
and place in the sterile field. 
 
4. Don sterile gloves. Uncap cold media tube under hood and hold while 10 ml syringe is 
filled. Once syringe is filled, tube is removed from hood. Cold media is dispensed on the 
work surface to keep fibers from drying out during the filling process. Syringe with the 
remaining media is placed in the sterile field. 
 
5. Carefully mix cell suspension to create homogeneity. Under the hood, uncap the cold 
cell suspension tube and fill a 1 ml syringe; place it in a sterile field within the hood. 
Remove lid from pipette tray and, with sterile forceps, remove 2–3 fibers and place on 
medium-soaked work surface. Flush each fiber intraperitoneally with cold medium to 
remove water. 
 
6. Create an air bubble in the 1 ml syringe containing the cell suspension so that the 
remaining medium can be pushed out of the fiber before filling it with the cell 
suspension. Insert needle into one end of the fiber. With the needle pointing upwards, 
form an upside-down “U” with the fiber before dispensing air bubble and cell suspension 
(Fig. 2). Fill fiber with cold cell suspension avoiding air bubbles in the fiber (see Note 4). 
 
Figure 2. Filling the fibers with cells. Medium containing cells is gently injected into the sterile 
fiber behind a cushion of air, replacing the medium lacking cells. 
  
7. Once the total length of the fiber is filled with the cell suspension, create a “d” by 
taking the loose end of the fiber and moving it horizontally to the work surface (Fig. 3). 
Heat the needle holder in the bead sterilizer for a few seconds and heat-seal the open end 
by clamping down on the fiber with the needle holder. Then heat-seal the other end just 
below the needle. Lay the filled fiber on the work surface. Continue until each of the 2–3 
fibers is filled. Be sure to keep fibers from drying out by keeping them covered with cold 
media. 
 
Figure 3. The ends of the fibers containing cells are sealed by pinching with a heated hemostat. 
  
8. One at a time, the filled fibers are laid across the area of the work surface that has the 2 
cm demarcations. Again heating the needle holder a few seconds, a mark is made every 2 
cm for the length of the fiber by pressing the needle holder closed on the fiber (Fig. 4). 
Repeating the process above a second time at each mark this time applying a slightly 
pulling action on the fiber creates a clear area that completes the heat-seal. Cut in the 
center of the heat-seal to make individual fibers for implantation. 
 
Figure 4. Cutting the individual fibers for implantation. Using a heated hemostat, clamp down 
firmly on the cell-filled fibers at 2 cm intervals. Using a scalpel or surgical scissors, cut the fibers 
in the middle of the heat-seal to generate the individual fibers for implantation. 
  
9. Fibers are placed into each well of a 6-well culture plate filled with 2 ml of medium 
supplemented with serum but lacking antibiotics. Place fibers in a 37  °C incubator 
(see Note 5). 
  
3.4 Implantation of Fibers 
 
1. Remove 6-well plates containing fibers from the incubator and check for sterility. 
Three fibers from each cell line are set aside to serve as “day 0” controls (see below). 
  
2. Anesthetize female athymic mice NCr nu/nu mice at 5–6 weeks of age with a 
combination of ketamine and xylazine (see Note 6). 
  
3. Lay mouse on its side and make a small incision through the skin and muscle layers 
just below the spleen. The size of the incision should be just large enough to 
accommodate the diameter of the fibers. Carefully handle fibers with forceps avoiding 
excess pressure and place the appropriate fibers in the abdominal cavity. Suture the body 
wall incision and use a wound clip to close the skin incision. 
  
4. Lay the same mouse on its stomach and make a small incision at the nape of the neck. 
Fill trocar with appropriate fibers, insert trocar into the incision, and place fibers over the 
hip region as you begin to withdraw trocar. Repeat until the appropriate number of fibers 
is placed in the animal. Close incision with a wound clip. 
  
5. Place animals back in cage and allow them to recover. Intraperitoneal injections of test 
compounds begin on day 3 after implantation and are usually injected daily for 4 days. 
Animal body weights are recorded every day to monitor compound toxicity (see Note 7). 
  
6. On day 7, animals are sacrificed and fibers are retrieved and placed in 6-well plates 
filled with warm media. Wells are labeled according to treatment and site of 
implantation. Fibers are placed in the incubator for at least 30 min to allow cells to 
normalize. 
  
7. The viable cell mass is evaluated by the MTT assay described below. The percent net 
growth for each cell line in each treatment group is calculated by subtracting the day-zero 
absorbance from the day 7 absorbance and dividing this difference by the net growth in 
the day 7 vehicle-treated controls minus the day-0 values. A 50% or greater reduction in 
net cell growth in the treated samples compared to the vehicle control samples is 
considered a positive result (see Note 8). 
  
3.5 MTT Assay 
 
We have modified this commonly used assay, which measures the reduction by metabolically 
active cells of a yellow tetrazolium salt to a purple formazan. The procedure has been modified 
for the HFA from published standard protocols (10, 11). 
 
1. Prepare stock solution of 5 mg/ml MTT. Store at 4  °C and protect from light. 
  
2. Prepare a 2.5% solution of protamine sulfate in saline and sterilize by passing through 
a 0.2 μm filter; store at 4  °C. 
  
3. Prepare a 1 mg/ml working solution of MTT by adding 4 ml of media to 1 ml of stock 
solution. Warm in a 37  °C water bath. 
  
4. Add 1 ml of working solution to the 2 ml of media for each well containing harvested 
fibers. Incubate for 4 h in cell culture incubator. 
  
5. Aspirate all liquid from each well. Wash fibers by adding 2 ml of 2.5% protamine 
sulfate to each well containing fibers. Store at 4  °C overnight. 
  
6. Aspirate liquid and perform a second wash with 2.5% protamine sulfate. Incubate at 4 
 °C for at least 2 h. Remove fibers and gently dry with a KimWipe. Cut fiber in half and 
place one fiber per well of a 24-well plate making sure that each well is labeled with 
correct treatment and placement. 
  
7. Allow the fibers to dry overnight protected from light (see Note 9). 
  
8. Add 250 μl of DMSO to each well and cover plate with foil. Place plates on a shaker 
for 4 h. 
  
9. Remove 150 μl of solution from each well and place in a 96-well plate. Read 
absorption at 490 nm on a microplate reader. 
  
4. Notes 
 
1. The cell lines are selected from the list of 30 lines used in the HFA developed by Hollingshead 
et al. (12). Since we are looking for new proteasome inhibitors, we have chosen lines that are 
most sensitive to bortezomib, an FDA-approved proteasome inhibitor. This information was 
obtained by querying the database of therapeutics for their activity against the NCI’s 60 cell line 
panel (13). 
  
2. Several methods are acceptable for sterilizing the hemostat used to seal the fibers. We use a 
glass bead sterilizer because it can rapidly heat and sterilize metal instruments such as the 
hemostat that is used to heat-seal the cell-filled fibers. 
  
3. Each cell line requires its own set of equipment to avoid cross-contamination. 
  
4. Each cell line should be represented by a different color fiber. If a fiber dries out in the process 
(turns white), it is unusable. 
  
5. Incubation allows cells to attach to the fiber surface prior to implantation in the mice. Six 
fibers are not implanted in the mice, but remain in the incubator and are harvested when the mice 
are sacrificed to assure that they are free of microbial contamination. 
  
6. Although most laboratories use immunodeficient mice, Shnyder et al. (14) have reported that 
immunocompetent mice such as NMRI also can be used at significantly lower cost. Ketamine 
and xylazine are administered by intraperitoneal injection at 100 and 10 mg/kg, respectively. 
  
7. The dose levels chosen for each test compound are determined by performing acute toxicity 
tests for each agent as described by the NCI Developmental Therapeutics Program (15). One 
mouse is given a single ip injection at 400 mg/kg body weight; another mouse is administered 
300 mg/kg and a third mouse is given 100 mg/kg. The mice are observed for 2 weeks and 
sacrificed if they lose 20% or more of their body weight or exhibit outward signs of toxicity as 
indicated above. If all three mice die or must be sacrificed, three lower doses (e.g., 50, 25, and 10 
mg/kg) are tested. The process is repeated until the maximum tolerated dose (MTD) is identified. 
We routinely use 40% of the single-dose MTD as the highest dose in our four-daily-dose 
treatment schedules. The initial level of exposure that we choose for the acute toxicity study is 
based on the activity of the compound in cell cytotoxicity tests. 
  
8. In the HFA, the measure of efficacy is the percentage reduction in cells at day 6 as compared 
to day 0 (implantation date): 
%netreduction = (day0OD540−day6OD540)
day0OD540 ×100%
 , 
where OD540 is the optical density measure of cell numbers. Because the maximum reduction is 
100%, nonlinear regression modeling of dose effects should be used. Models would be estimated 
separately for implant site (subcutaneous vs. intraperitoneal), and for each cell line. The 
maximum dose can be determined from prior toxicity studies. With multiple estimated models 
per compound, some approach to decision making about further experimentation (e.g., xenograft 
testing) with the compound must be chosen. Depending on circumstances, an investigator can 
choose to focus on minimizing false negatives (possibly missing promising compounds) or false 
positives (expending further resources on ineffective compounds). 
 
Decker et al. (12) developed a scoring system that seems to emphasize avoidance of false 
positives. Based on their recommendation, promising compounds are those that are effective 
across multiple cell lines. They validate their scoring system through the prediction of success in 
multiple xenograft models. A score is considered low if a compound acts only on one cell line. 
They also recommend further testing of any compound that produces 100% cell death. Therefore 
if one were most concerned about false negatives, such a scoring system would not be optimal. 
Instead, one could base the decision to move forward with a compound on the percent net 
reduction observed at the maximum dose for a particular cell line. A confidence interval on the 
percent net reduction estimate would be useful to take into consideration sampling error of the 
estimate. A more formal decision procedure could test the significance of the dose–response 
curve, and use liberal criteria for declaring a positive result. The number of cell lines and 
compounds tested simultaneously must be considered when deciding on such criteria. This 
approach further allows for a second more precise study when results are too variable to achieve 
significance. 
  
9. We place the plates containing the fibers near the vent of a biological safety cabinet with some 
foil loosely applied to protect the dye from light. 
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